about
Cushing's diseaseUpdate in the medical therapy of Cushing's diseaseThe Treatment of Cushing's Disease.Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.Update on medical treatment for Cushing's disease.EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.Effects of RXR Agonists on Cell Proliferation/Apoptosis and ACTH Secretion/Pomc Expression.Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice GuidelineMedical management of Cushing's disease: what is the future?SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells.Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.Evidence for orphan nuclear receptor TR4 in the etiology of Cushing diseaseLoss of Efficacy of Pasireotide After its Re-Administration: is There a Reason Why?Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas.Mifepristone: is there a place in the treatment of Cushing's disease?Efficacy of medical treatment in Cushing's disease: a systematic review.Medical management of Cushing's disease.Surgical management of adrenocortical tumours.The adrenal psoas sign: surgical outcomes following a simple technique to maximize removal of extracortical adrenal tissue during bilateral laparoscopic adrenalectomy.Detection of recurrent Cushing's disease: proposal for standardized patient monitoring following transsphenoidal surgery.Update on radiation therapy in patients with Cushing's disease.Clinicopathological correlates of adrenal Cushing's syndrome.The role of genetic and epigenetic changes in pituitary tumorigenesis.New potential targets for treatment of Cushing's disease: epithelial growth factor receptor and cyclin-dependent kinases.Approach to the postoperative patient with Cushing's disease.Incremental healthcare resource utilization and costs in US patients with Cushing's disease compared with diabetes mellitus and population controls.Emerging drugs for Cushing's disease.Cushing's syndrome: an update on current pharmacotherapy and future directions.A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease.Long-Term Outcome of Bilateral Laparoscopic Adrenalectomy Measured by Disease-Specific Questionnaire in a Unique Group of Patients with Cushing's Syndrome.Currently used and investigational drugs for Cushing´s disease.Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma.A new medical therapy for Cushing disease?Recommendations of the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism for the diagnosis of Cushing's disease in Brazil.Synchronous bilateral adrenalectomy by midline incision: A reliable method for treatment of hypercortisolism.Treatment patterns in Cushing's disease patients in two large United States nationwide databases: application of a novel, graphical methodology.A Long-Term Study of the Treatment of Nelson's Syndrome With Gamma Knife Radiosurgery.The anterior skull base nasal inventory (ASK nasal inventory): a clinical tool for evaluating rhinological outcomes after endonasal surgery for pituitary and cranial base lesions.Outcome of endoscopic vs microsurgical transsphenoidal resection for Cushing's disease.Pharmacophore Modeling and in Silico/in Vitro Screening for Human Cytochrome P450 11B1 and Cytochrome P450 11B2 Inhibitors.
P2860
Q26827386-50087A11-1CE2-4A74-9EA4-5EAB4AE02C85Q26865203-FF826FC3-E8EA-48C1-8594-6DB3FB442B17Q27010590-331AC634-CD7F-4D71-B290-4132E9B88445Q33570330-40553CCE-95A5-474A-96ED-AF8CAAC73940Q33802284-90E50205-5B3C-4402-83E9-B537046B0E50Q35578652-21ED237C-53F5-48D2-A079-3D182EEAE7BAQ35880635-D5135D05-B43C-4728-91F6-C2D5AF2E1906Q35916555-B877913B-2EB9-4AC2-8015-C6ABE6F55907Q36236884-42F5C66E-6058-43BC-AFB9-7FEC2103F3C4Q36382533-4FA84A8D-2492-4700-9670-7C958DC0DC23Q36704499-660C39A6-A3BE-47D6-8690-D9B7DD6349C7Q36884281-03A4FE0C-214D-4537-8B1A-D016EED30A35Q37579710-28A40B57-4564-4E61-B1B1-E4E44BF43A76Q37950869-AA25108E-6581-4CFB-9D35-6CA99D64A68BQ38063404-4FC05E85-A64E-4320-B218-A84EE0315680Q38151882-40F01498-1320-40B9-AD33-F573D8B9B040Q38154515-E1925383-66D8-4DC2-A304-D93DF7D6C3CCQ38196681-35681536-5A71-4B86-BB18-03DBF332E7E4Q38206943-B8BCE908-5D1E-468F-AF93-02C1F17BDF3BQ38224779-82798A0C-AC3C-494E-993D-0FE175E77719Q38264073-DFA73A60-D6A2-44A8-B732-412854DEB47AQ38271545-4D954AA7-6305-4CCD-9485-B0968C2E2170Q38274982-088847D5-6526-4CB3-95BE-05C5823E8FB1Q38328843-51B73700-B770-4417-855A-50C7F7027923Q38363541-103D1B92-EB84-4AA3-A894-F82D4C8EBC5DQ38405559-4A835393-7E7E-48E0-BC71-31C1575D3509Q38505947-E6281711-9E1B-44DB-90BD-E8249200EC66Q38541695-5FA3E362-3110-4667-B7B2-866892FB5951Q38911503-67CE10DB-8633-4408-91E5-A22885B12F13Q39007480-74C41D2A-01B7-488B-96FF-E4851DEB6EDEQ39022297-BD983F43-8FBA-4F6F-8C59-B1FB5A0216DFQ39074559-D313C680-2B92-41B5-84E4-8F7DC97B8C5BQ39449846-2FE93AE3-3AEF-40B4-832C-233978A92E27Q40632126-8DEB006F-32DC-476C-9719-A2A7161A7073Q42323321-AE175FE3-DDCE-4C60-9DC0-325E9F24D72EQ43656346-B458C9BB-D565-4AE7-AD65-9E77B3A811B2Q45068429-A91E368B-47AD-42D3-A00E-D709EA51035EQ48806019-3B2DD3E1-3FD8-46CD-B69F-B3256B4E6BE8Q49218528-B768FB75-C0C9-4EBC-BD95-C9EE3EBDB0ECQ50128659-43D7E5E4-93D5-4BAF-8CBA-3BD3C67B61EC
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management of Cushing disease.
@en
Management of Cushing disease.
@nl
type
label
Management of Cushing disease.
@en
Management of Cushing disease.
@nl
prefLabel
Management of Cushing disease.
@en
Management of Cushing disease.
@nl
P2093
P2860
P356
P1476
Management of Cushing disease.
@en
P2093
Beverly M K Biller
Brooke Swearingen
Nicholas A Tritos
P2860
P2888
P304
P356
10.1038/NRENDO.2011.12
P577
2011-02-08T00:00:00Z